Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Cell Immunol. 2021 Aug 24;369:104426. doi: 10.1016/j.cellimm.2021.104426

Figure 3:

Figure 3:

Expression levels of (a) HMGB1 and (b) ADAM17 were evaluated using the ELISA platform in serum of participants with active TB disease (n = 20) at the time of diagnosis/baseline (BL), one month (M1) and six months (M6) after the initiation of treatment. D’Agostino & Pearson Omnibus test for normality was used to determine the distribution of the protein data, after which the statistics used for HMGB1 were parametric (repeated measures one-way ANOVA and Tukey’s test for multiple comparisons), while the statistics used for ADAM17 were non-parametric (Friedman test and Dunn’s test for multiple comparisons). Error bars represent the median and range. ***P < 0.001; **P < 0.01; *P < 0.05; ns: not significant.